Aardvark Therapeutics adds Abivax CSO David Zhang to board as ARD-101 regulatory decisions loom
Aardvark Therapeutics, Inc.
David Zhang, Ph.D., MBA, appointed independent Class II director effective Oct. 7, 2026; he is Chief Strategy Officer of Abivax S.A. and a member of its Executive Committee.
Zhang paid $40,000/year prorated cash plus a $500,000 option granted Oct. 7, 2026 that vests 1/36 monthly and accelerates in full on a change in control.
At Abivax he led biometrics through positive topline readouts of two pivotal Phase 3 trials of obefazimod in ulcerative colitis.
At MyoKardia he oversaw pivotal trial design, readout and the NDA for CAMZYOS (mavacamten) before the Bristol Myers Squibb acquisition; earlier 15 years at Genentech/Roche.
Zhang said Aardvark is 'at a pivotal moment, with important decisions ahead for ARD-101' and cited navigating the regulatory landscape in Prader-Willi Syndrome.
On October 6, 2026, the board of directors (the “Board”) of Aardvark Therapeutics, Inc. (the “Company”) appointed David (Zhongwei) Zhang, Ph.D., MBA, as a Class II director of the Company, effective October 7, 2026.
Key facts
Extracted from this filing and checked against the source text.
Executive changeSEC 8-K Item 5.02confidence 0.95
David (Zhongwei) Zhang was appointed as Class II director at Aardvark Therapeutics, Inc..
Action
appointed
Role
Class II director
Exact text from the filing
On October 6, 2026, the board of directors (the “Board”) of Aardvark Therapeutics, Inc. (the “Company”) appointed David (Zhongwei) Zhang, Ph.D., MBA, as a Class II director of the Company, effective October 7, 2026.
This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.